Federal Judge Challenges Recent Mifepristone Drug Restrictions Affecting Abortion Access in Florida

Last updated: July 25, 2026

NewsWK — A federal judge in Virginia has ruled that the U.S. Food and Drug Administration (FDA) did not adequately justify its restrictions imposed on mifepristone, a medication used for early pregnancy termination. This decision adds complexity to ongoing legal battles that may influence abortion access in Florida and beyond.

The lawsuit, initiated in 2023 by abortion providers from Kansas, Montana, and Virginia, argues that the FDA’s restrictions are excessive and inconsistent with other legal standards. Similar findings were reached in a case in Hawaii last October, where a federal judge also deemed the restrictions arbitrary.

Judge Robert Ballou, appointed by former President Joe Biden, stated that the FDA failed to undertake a proper review of the regulations concerning mifepristone. These regulations require that prescribing pharmacies and clinicians be specially certified and that both prescribers and patients sign forms acknowledging the risks associated with the medication.

“The 2023 REMS modification is unlawful and must be remanded to the FDA for review,” Ballou wrote, referring to the FDA’s Risk Evaluation and Mitigation Strategies protocols. Amy Hagstrom Miller, president and CEO of Whole Woman’s Health Alliance, a lead plaintiff in the case, expressed that removing these restrictions would enable clinic staff to better focus on patient care rather than excessive administrative tasks. She stated, “I have worked in abortion care for over 30 years, and I can attest that these regulations serve no medical purpose, nor do they add value to our patients’ experience of abortion.”

Although the FDA has not commented on this ruling, it is currently conducting a broader safety review concerning mifepristone, which may affect the legal landscape surrounding the medication. This review is expected to take approximately six months, potentially concluding after the upcoming national midterm elections.

Meanwhile, pressure from anti-abortion advocates continues, urging the administration to impose further restrictions on mifepristone, even in states where abortion remains legal. The 2023 rules, enacted under the Biden administration, had previously eased certain requirements, allowing mifepristone to be dispensed without an in-person visit for the first time. This change significantly expanded access to the medication, particularly for individuals in states with stringent abortion laws, such as those in Florida.

As legal scrutiny continues, additional lawsuits are underway, including one in Louisiana concerning telehealth prescriptions and another in Texas spearheaded by Florida’s attorney general aiming to revoke the drug’s approval entirely.